Of note, a decreased expression of metallothionein (MT) family genes, including MT2A, MT1X, and MT1E, has been previously associated with resistance to anti-PD-1 therapy in ESCC [64]. The gene discussed is MT2A; the disease is esophageal squamous cell carcinoma.